Full-Time
Director Commercial Operations and Analytics
Posted on 7/29/2026
Secura Bio
51-200 employees
Commercializes oncology therapies and develops COPIKTRA
Compensation Overview
$208k - $254k/yr
Remote in USA
Remote
 Business & Strategy (1) |
|---|
Get referred to Secura Bio
See people who can refer or advise you
- A bachelor's degree in business, Economics, Statistics, Data Science, or a related field is required.
- Demonstrated expertise in forecasting, market research, Microsoft Suite, M365 Copilot, Excel, SQL, Tableau, and Power BI is required.
- A strong understanding of pharmaceutical industry datasets, sources, and related operational infrastructure is required.
- Excellent communication and presentation skills are required, including the ability to translate complex data into actionable insights.
- Experience with data warehouse management and data governance best practices is required.
- Understanding of datasets including 867, 852, Specialty Pharmacy, Longitudinal Claims Data, and Market Research is required.
- Vendor management experience is required.
- Support forecasting and long-range planning for in-line business needs, business development, and launch planning.
- Conduct scenario planning and sensitivity analyses to inform strategic decisions.
- Manage third-party vendor support for building and managing dashboards and reporting tools that track key performance indicators, sales performance, channel and distribution metrics, and market access metrics.
- Develop field incentive compensation plans, including goal setting.
- Deliver actionable insights to senior leadership through clear, concise presentations and reports.
- Oversee data warehouse architecture and data management, and ensure data integrity across multiple sources.
- Implement best practices for data governance and compliance with regulatory standards.
- Collaborate on pricing analyses and support group purchasing organization and specialty pharmacy strategy.
- Provide analytics to optimize reimbursement and access strategies across markets.
- Support primary and secondary market research projects to assess market dynamics, competitive landscape, and patient needs.
- Manage and analyze syndicated data sources such as IQVIA, Symphony, and Komodo, as well as claims-level data, to identify trends and opportunities.
- Create, analyze, and present monthly and quarterly business reviews to leadership.
- Partner with Sales, Marketing, Market Access, Finance, and Medical Affairs to align analytics with business objectives.
- Lead ad hoc analyses for strategic initiatives and business development opportunities.
- Serve as the analytical lead across the commercial operations team as needed.
- An advanced degree or certification in statistics or advanced analytics is preferred.
- Experience with artificial intelligence tools is preferred.
- 10+ years of experience in commercial analytics within the pharmaceutical or biotech industry is preferred.
Secura Bio is an integrated biopharmaceutical company focused on bringing oncology therapies to patients. Its main product is COPIKTRA (duvelisib), an oral PI3K inhibitor used to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The company is also running a Phase 3 study of COPIKTRA for relapsed or refractory nodal T-follicular helper cell lymphoma. Secura Bio’s approach centers on acquiring, developing, and commercializing approved and late-stage oncology assets, with headquarters in Las Vegas and a European office in Dublin. In simple terms, the company buys or develops cancer drugs and then brings them to doctors and patients who need them. Its goal is to close the gap between available oncology therapies and the patients who can benefit from them.
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$55M
Headquarters
Mesa, Arizona
Founded
2019
Get referred to Secura Bio
See people who can refer or advise you
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -1%2 year growth
↓ -3%Secura Bio expands Chief Financial Officer Will Brown's leadership role to include Chief Operating Officer. BERKELEY HEIGHTS, NJ, February 11, 2026 (GLOBE NEWSWIRE) - Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will Brown, currently serving as Chief Financial Officer, has been appointed to the additional role of Chief Operating Officer. In this expanded capacity, Mr. Brown will oversee daily operations, ensuring alignment with the company's strategic goals, while continuing to lead Secura Bio's financial operations and strategic planning. "Will has been instrumental in shaping our financial foundation and driving operational rigor with his extensive knowledge of the biopharmaceutical industry and deep understanding of our business," said Chip Romp, Chief Executive Officer of Secura Bio. "Expanding Will's role to include additional responsibilities as COO is a natural move for us given his exceptional leadership. Will's strategic perspective and insights will be essential to Secura Bio as we continue to embark on our bold vision to change outcomes in human health by expanding the potential of oncology medicines." Mr. Brown added, "Secura Bio is well positioned to scale and grow, and I'm excited by our long-term prospects to commercialize transformative therapies for patients while building substantial value for shareholders. I'm honored to work with such an incredible team and am inspired by the shared commitment and focus brought to work each day as we focus on our strategic initiatives to build a world-class biopharmaceutical company." Mr. Brown joined Secura Bio as Chief Financial Officer in 2024. Prior to Secura Bio, Mr. Brown served as Chief Financial Officer and Interim Chief Executive Officer at ObsEva SA, where he successfully led the company through a restructuring that generated a strategic disposition of over $100 million. Prior to ObsEva SA, Mr. Brown served as the Chief Financial Officer of Altimmune, Inc., where he was critical in the transformation and growth of the company, guiding them through more than $300 million in new equity issuances and a strategic acquisition. Prior to his pharmaceutical industry roles, Mr. Brown was a consultant to private and public companies in a variety of accounting and financial matters as managing partner of Redmont Advisors and CPAs. Mr. Brown earned both his MBA and BS in accounting from Auburn University Montgomery. About Secura Bio, Inc. Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies for physicians and their patients. For more information on Secura Bio, please visit https://www.securabio.com/. Investor & Media Contact Will Brown CFO & COO Phone: 334-313-2319 [email protected] Media Contact Kit Rodophele Ten Bridge Communications Phone: 617-999-9620 [email protected]